AMBRISENTAN 10 MG TABLET
For 30 tablets
Pharmacies pay
$240.74 filed
30 × $8.02453 per EA
CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17
Medicare Part D paid
$2,977.12 filed
30 × $99.23742 per EA, Part D average
Medicare's price is not your price.
Medicare Part D · DSD_PTD_RY26_P04_V10_DY24_BGM.csv · eff. 2024-01-01 to 2024-12-31 · as of 2026-06-25 · retrieved 2026-10-18
The spread
12.4× estimated
Medicare paid 12.4× what pharmacies pay.
Part D averages every strength and form sold under “Ambrisentan” into one figure, so it is not specific to this NDC.
OpenBill calculation · DSD_PTD_RY26_P04_V10_DY24_BGM.csv + nadac-national-average-drug-acquisition-cost-20261014.csv · NADAC eff. 2026-09-23 (file of 2026-10-14, retrieved 2026-10-17) · Part D 2024-01-01 to 2024-12-31 (file of 2026-06-25, retrieved 2026-10-18)
Cost-plus estimate
$281.85 estimated
$240.74 + $36.11 (15%) + $5.00 fee per fill = $281.85
This is a model, not a price any pharmacy quoted. Shipping is not included. How it is worked out
OpenBill calculation · nadac-national-average-drug-acquisition-cost-20261014.csv · NADAC eff. 2026-09-23 (file of 2026-10-14, retrieved 2026-10-17)
Open the interactive card Change the quantity, type what you were charged, and see every record in full.
What it is
AMBRISENTAN 10 MG TABLET is how the CMS NADAC file names this product. The FDA NDC Directory lists it as ambrisentan.
FDA gives its dosage form as tablet, film coated and its route as oral.
FDA lists 9 labelers (the companies named on the label) for its NDCs, among them Mylan Pharmaceuticals Inc., Actavis Pharma, Inc. and Sigmapharm Laboratories, LLC.
FDA’s Established Pharmacologic Class for it is Endothelin Receptor Antagonist.
The NADAC file of 2026-10-14 prices it under 9 NDCs (National Drug Codes).
NADAC classes it as a generic drug (rate-setting class G), and does not mark it as sold over the counter.
What pharmacies pay
Pharmacies pay $240.74 for 30 tablets (30 × $8.02453 per EA, rounded to the cent), by the CMS NADAC file of 2026-10-14; that price took effect on 2026-09-23. That is what pharmacies pay their suppliers, not what they charge you.
NADAC’s explanation code for it: 1, calculated from the most recently completed pharmacy survey.
What NADAC measures · Why 30 tablets · NADAC explanation codes
The 9 labelers
| Labeler | NDCs | Pharmacies pay per unit |
|---|---|---|
| Actavis Pharma, Inc. | 1 | $8.02453 per EA filed |
| Apotex Corp. | 1 | $8.02453 per EA filed |
| Aurobindo Pharma Limited | 1 | $8.02453 per EA filed |
| Cipla USA Inc. | 1 | $8.02453 per EA filed |
| Mylan Pharmaceuticals Inc. | 1 | $8.02453 per EA filed |
| Quallent Pharmaceuticals Health LLC | 1 | $8.02453 per EA filed |
| Sigmapharm Laboratories, LLC | 1 | $8.02453 per EA filed |
| Sun Pharmaceutical Industries, Inc. | 1 | $8.02453 per EA filed |
| Zydus Pharmaceuticals USA Inc. | 1 | $8.02453 per EA filed |
All 9 NDCs, with labeler and price
- 00378-4271-93 · Mylan Pharmaceuticals Inc. · $8.02453 per EA · eff. 2026-09-23 filed
- 00591-2406-30 · Actavis Pharma, Inc. · $8.02453 per EA · eff. 2026-09-23 filed
- 42794-0052-08 · Sigmapharm Laboratories, LLC · $8.02453 per EA · eff. 2026-09-23 filed
- 47335-0237-83 · Sun Pharmaceutical Industries, Inc. · $8.02453 per EA · eff. 2026-09-23 filed
- 59651-0495-30 · Aurobindo Pharma Limited · $8.02453 per EA · eff. 2026-09-23 filed
- 60505-4553-03 · Apotex Corp. · $8.02453 per EA · eff. 2026-09-23 filed
- 69097-0387-02 · Cipla USA Inc. · $8.02453 per EA · eff. 2026-09-23 filed
- 70710-1180-03 · Zydus Pharmaceuticals USA Inc. · $8.02453 per EA · eff. 2026-09-23 filed
- 82009-0142-30 · Quallent Pharmaceuticals Health LLC · $8.02453 per EA · eff. 2026-09-23 filed
What Medicare paid
Medicare Part D paid $2,977.12 for 30 tablets, at an average of $99.23742 per EA in 2024 (2024-01-01 to 2024-12-31) for “Ambrisentan”, every strength and form sold under that name together (Medicare Part D Spending by Drug, file of 2026-06-25).
That average covers 58,711 Part D claims (fills, including refills) for 2024-01-01 to 2024-12-31, across every maker, strength and form under the name.
Medicare's price is not your price.
What Part D spending measures · Which Medicare figure OpenBill compares · How the spread is worked out
What to ask at the counter
None of these figures is your price: what you pay depends on your pharmacy, your insurance, coupons and discounts.
- What is your cash price for 30 tablets? Is it lower than what I would pay through my insurance?
- If you have Medicare Part D: what is my plan’s copay or coinsurance for it? The Part D average on this page is not what you pay.
- These are questions about price, not medical advice. Do not change or stop a medicine without talking to your prescriber or pharmacist.
Questions
- Why is the comparison with Medicare for AMBRISENTAN 10 MG TABLET labelled estimated?
- Beyond what the card shows, the records give these reasons: The Part D figure covers 2024-01-01 to 2024-12-31; the NADAC price is from the file of 2026-10-14. Part D spending basis, as the Part D record states it: Part D 2024 average spend per dosage unit for Ambrisentan / Ambrisentan: all makers, strengths, forms and routes combined, claim-weighted; gross cost incl. dispensing fees and patient pay, before rebates. Unit taken as NADAC's EA. Joined on generic name.